Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.
3 independently sourced, verified news trends involving Price Target Raised.
This hub is built from stories supported by at least four independent sources and accepted by Newsylist's verification pass. Qualifying coverage spans 1 news category, from Jun 25, 2026 through Jul 14, 2026.
Open any card for the source list, timeline and coverage-velocity evidence. Raw detections and extractive-only records are excluded from this page.
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.
FuelCell Energy shares surged 24% while Bloom Energy fell 14%, marking a sharp divergence in the fuel cell sector.
Darden Restaurants shares fell as a profit beat was overshadowed by weakening growth at Olive Garden.